Drilldown: Medicines

7-Hydroxymitragynine (1) · Acetylfentanyl (1) · Alfentanil (1) · Butorphanol (1) · Carfentanil (1) · Codeine (2) · Desomorphine (1) · Dextropropoxyphene (1) · Diacetylmorphine (1) · Dihydrocodeine (1) · Ethylmorphine (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Kratom (1) · Levorphanol (1) · Meperidine (1) · Mitragynine (1) · Nalbuphine (1) · O-Desmethyltramadol (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Polyethylene glycol 3350 (PEG 3350) (1) · Polyethylene glycol 3350 with electrolytes (1) · Remifentanil (1) · Sufentanil (1) · Tapentadol (1) · Thebaine (1) · Tianeptine (1) · U-47700 (1)

None (12) · (multiple, generic dominant) (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · GoLYTELY, NuLYTELY, TriLyte, MoviPrep, Plenvu, Gavilyte (1) · Heroin (1) · Krokodil (1) · MiraLAX (OTC), GlycoLax, GoLYTELY (with electrolytes for bowel prep), CoLyte, MoviPrep, NuLYTELY (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Stablon (1) · Stadol (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Active metabolite of tramadol; mu-opioid agonist (1) · Extremely potent mu-opioid receptor agonist (1) · Highly potent mu-opioid receptor agonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; fentanyl analogue (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Opioid receptor partial agonist/antagonist; toxic alkaloid (1) · Partial mu-opioid receptor agonist; alpha-2 agonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (6) · Prodrug of morphine; mu-opioid receptor agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Selective mu-opioid receptor agonist (1) · Ultra-short-acting mu-opioid agonist (1) · '"`UNIQ--vote-00000054-QINU`"' The clinical efficacy endpoint is adequate visualization at colonoscopy, scored by the Boston Bowel Preparation Scale'"`UNIQ--ref-00000055-QINU`"'. (1) · '"`UNIQ--vote-0000132D-QINU`"' Electrolyte-balanced bowel-prep formulations are designed to be iso-osmotic with plasma so the volume passes through without net fluid or electrolyte shifts, the basis of their safety for whole-bowel evacuation. (1)

None (29) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"' (1) · '"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"' (1)

None (29) · 4 L oral solution (GoLYTELY-class) split-dose: 2 L evening before, 2 L morning of procedure; low-volume products (MoviPrep, Plenvu) use 1-2 L with required clear-fluid intake (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1)

None (29) · 17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY) (1) · Powder for oral solution in 4 L jugs (PEG 3350 ~236 g + NaCl, NaHCO3, KCl, Na2SO4) and low-volume packets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (29) · 360 mg/day (1) · 4 L per procedure (standard-volume products) (1) · Indication-specific; bowel prep regimens reach 4 L cumulative (1)

None (29) · Oral (2) · PO (only formulation marketed in the US). (1)

None (29) · 30–60 min (PO) (1) · Constipation: 1-3 days; bowel prep: 1-3 hours after starting (1) · First bowel movement within 1-2 hours (1)

None (29) · 4-6 hours (1) · 4–6 hours (1) · Hours (1)

None (29) · 2.5–3 hours (1) · Not absorbed (1) · Not meaningfully described (negligible systemic absorption) (1)

None (29) · <0.1% systemic absorption (PEG 3350 is too large to absorb intact) (1) · Negligible (not absorbed)'"`UNIQ--ref-00000058-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (29) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Generally considered safe due to minimal systemic absorption.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not absorbed; generally considered acceptable when bowel prep is required<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (29) · OTC (MiraLAX) and [[USLegal:Prescription only|Rx-only]] (electrolyte solutions for bowel prep) in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (most products; some low-volume packs OTC) (1)